I've heard about this drug before and didn't realize until recently that it was the same as the drug most Transgendered individuals call simply "spiro." The feminizing effects of this drug are not listed here. As a MTF Transgenderist individual my self; that's how I initially found out about what "spiro" is. I did not however know Spironolactone was infact the "spirp" in question. To clarify transgenderist is a term used for individuals who want gender characteristic altering procedures short of Gender/sexual reassignment surgery(also known as a sex change, or "bottom surgery). I'd honestly like to know why; gynecomastia(benign breast enlargement), feminization in general, testicular atrophy, and sexual dysfunction consisting of loss of libido, and erectile dysfunction are not listed as side effects for men. Also why aren't menstrual irregularities and breast tenderness and enlargement listed as side effects for women?
Its not classified as it, because it isn't one. Its a potassium sparing diuretic. It antagonizes aldosterone specific corticoid receptors.
Spironolactone is not listed as a anti-angrogen because it isn't, it is the generic form of Aldactone, a potassium sparing diuretic. It's normal dose is 12.5 to 25mg as as diuretic and to prevent scarring of heart muscle following a heart attack. At larger doses of 100 to 300 mg it is used as a source of potassium. You have broken the drug down the wrong, you want to first look up the medication and find out if it is a brand name or the generic form of another medication.
Using it in transgenders and for hirsutism is an "offlabel" use. It is not FDA approved for this use. That is why this information is not in the descriptions. And some of those side effects are listed under the professional listing:
Drowsiness; lethargy; headache; mental confusion; ataxia.
Maculopapular or erythematous cutaneous eruptions; urticaria.
Cramping; diarrhea; gastric bleeding; gastric ulceration; gastritis; vomiting.
Inability to achieve or maintain erection.
Hyperchloremic metabolic acidosis in decompensated hepatic cirrhosis.
Gynecomastia; irregular menses or amenorrhea; postmenopausal bleeding; hirsutism; deepening of voice; drug fever; carcinoma of breast.
Spironolactone interferes with 17-hydroxylase activity, which causes a decrease in testosterone synthesis. It also inhibits the intracellular binding of dihydrotestosterone to its receptor.
Rare cases of young women with liver disease who developed menarche only after spironolactone was discontinued are reported. Since estradiol synthesis is partially dependenton testosterone synthesis, spironolactone may cause primary or secondary amenorrhea in adolescents.
Endocrinologic side effects have been due to the antiandrogenic properties of spironolactone. Five percent to 30% of male patients complained of gynecomastia, impotence or diminished libido. Female patients reported hirsutism, oligomenorrhea, amenorrhea, menorrhagia, and breast tenderness. These side effects appeared to be dose-related, and were more likely during long-term therapy. Gynecomastia may be more likely in some male patients with liver disease due to the increased conversion of androgens to estrogens in severe liver disease.
Spironolactone has two roles: it's an aldosterone antagonist and an anti androgen. It blocks the androgen receptor which is the cytoplasmic receptor for dihydrotesterone (DHT) and it also inhibitors androgen biosynthesis. Spironolactone is not only a bonafide anti androgen but it's the most commonly used anti-androgen to treat female genetic hair loss in the United States.
- Spironolactone Information for Consumers
- Spironolactone Information for Healthcare Professionals (includes dosage details)
- Side Effects of Spironolactone (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Updated 7 Dec 2011 • 4 answers
Congestive Heart Failure - My doctor has me om several different meds, some related, Why would I be?
Updated 29 Jul 2016 • 4 answers
Updated 13 Sep 2016 • 1 answer
Updated 28 Jun 2016 • 1 answer
Updated 11 Jan 2019 • 1 answer